Evidence map›Paper›PMID 31490566›Full record

ArticleClinical cardiology2019

Design and rationale for the "Me & My Heart" (eMocial) study: A randomized evaluation of a new smartphone-based support tool to increase therapy adherence of patients with acute coronary syndrome.

Florian Krackhardt, Lars S Maier, Karl-Friedrich Appel, Till Köhler, Alexander Ghanem, Carsten Tschoepe, Jürgen Vom Dahl, Ralf Degenhardt, Anna Niklasson, Matti Ahlqvist and 2 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in Clinical cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02615704 (Evaluation of an Electronic Device Based Support Tool for ACS Patients), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02615704 completednot on this map

Evaluation of an Electronic Device Based Support Tool for ACS Patients: Brilique (Ticagrelor) Treatment Adherence (eMocial)

TypeobservationalSponsorAstraZenecaRan2016 to 2019Enrolled677ConditionsAcute Coronary SyndromeArmsActive group with MEMS, Active group without MEMS, Control group with MEMS, Control group without MEMS
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Florian KrackhardtDepartment of Internal Medicine and Cardiology, Charité Campus Virchow-Klinikum, Charité University Medicine Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0001-5965-8817
Lars S MaierKlinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany.
Karl-Friedrich AppelAmbulantes Herzzentrum Kassel, Kassel, Germany.
Till KöhlerUniversitätslinikum Wuppertal, Wupperthal, Germany.
Alexander GhanemAsklepios Klinik St. Georg, Hamburg, Germany.
Carsten TschoepeDepartment of Internal Medicine and Cardiology, Charité Campus Virchow-Klinikum, Charité University Medicine Berlin, Berlin, Germany.
Jürgen Vom DahlKliniken Maria Hilf GmbH/Medizinische Klinik II, Mönchengladbach, Germany.
Ralf DegenhardtInstitut für Klinische Forschung Herz- und Kreislaufzentrum GmbH, Fulda, Germany.
Anna NiklassonAstraZeneca R&D Gothenburg, Gothenburg, Sweden.
Matti AhlqvistAstraZeneca R&D Gothenburg, Gothenburg, Sweden.
Matthias W WaliszewskiDepartment of Internal Medicine and Cardiology, Charité Campus Virchow-Klinikum, Charité University Medicine Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0002-8689-4505
Magnus Jörnten-KarlssonAstraZeneca R&D Gothenburg, Gothenburg, Sweden.

Funding

AstraZeneca
6 · The paper itself

Abstract

A novel smartphone-based patient support tool was developed to increase the adherence to antiplatelet therapy and lifestyle changes in patients after coronary angioplasty for acute coronary syndrome (ACS). The eMocial study (ClinicalTrials.gov Identifier: NCT02615704) investigates whether an electronic support tool will improve adherence to comedication and lifestyle changes in ACS patients. The primary hypothesis of this trial is that an electronic support tool can increase adherence to comedication (primary endpoint) thereby supporting positive lifestyle changes (secondary endpoints). Patients hospitalized with ACS (ST elevation myocardial infarction [STEMI], non-ST elevation myocardial infarction [NSTEMI], or unstable angina pectoris) and treated with ticagrelor coadministered with low-dose acetylsalicylic acid will be randomized 1:1 to an active group receiving the patient support tool via a smartphone-based application or to a control group without the patient support tool. Patient questionnaires to evaluate lifestyle changes and quality of life will be used at baseline and at the end of the 48-week observation phase. Patients are asked to fill out questionnaires to determine their adherence, treatment attitudes, health-care utilization and risk factors on a monthly basis. The study was started in February 2016 and the completion date is scheduled for October 2019. For final analysis 664 patients are expected be available. Preliminary baseline demographics were unstable angina pectoris (13.7%), NSTEMI (49.9%), STEMI (36.4%), male gender (86.3%), and diabetes mellitus (17.6%). Our study could significantly help to understand how inadequate adherence to antiplatelet therapy in ACS patients could be improved with a smartphone-based application.

Indexed as

Patient ComplianceSmartphoneAcute Coronary SyndromeAngioplasty, Balloon, CoronaryElectrocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedPlatelet Aggregation InhibitorsPostoperative PeriodQuality of LifeRandomized Controlled Trials as TopicRetrospective StudiesSurveys and QuestionnairesPlatelet Aggregation InhibitorsTicagreloracute coronary syndromeadherencedual anti-platelet therapy (DAPT)smartphone-based supportstudy designticagrelor

Identifiers

PMID31490566
PMCPMC6837026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.